Group 1 - Major tech stocks in Hong Kong experienced a decline, with notable drops of approximately 4% for companies such as NetEase, Meituan, Bilibili, and Trip.com, while Baidu and Tencent fell over 3% [1][2] - The Hang Seng Index saw a broader market downturn, with a decline of 1% and the Hang Seng Tech Index dropping by 1.87% [2] - Specific stock performance included Kingdee International down by 4.98%, NetEase down by 4.15%, and Meituan down by 4.11%, among others [3]

最新定期报告显示，港股互联网ETF博时（159568）重仓股包括腾讯控股、阿里巴巴-W、小米集团- W、美团-W、商汤-W、快手-W、贝壳-W、京东健康、哔哩哔哩-W、金蝶国际，持仓占比如下。 股票代码股票名称持仓占比持仓股数（股）持仓市值（元）00700腾讯控股15.35%12.02万6503.17万 09988阿里巴巴-W14.43%47.39万6112.35万01810小米集团-W13.96%166.64万5915.14万03690美团- W12.30%55.85万5210.95万00020商汤-W4.08%869.70万1728.17万01024快手-W3.77%27.65万1597.09万 02423贝壳-W3.73%42.18万1581.06万06618京东健康3.71%31.35万1571.54万09626哔哩哔哩-W3.30%8.03 万1398.38万00268金蝶国际3.25%114.70万1376.84万 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 bi ...

Core Insights - JD Health has launched a special user appreciation campaign for the Spring Festival, collaborating with various health brands to offer customized health gift packages to loyal users [1][3] Group 1: User Engagement and Loyalty - The campaign targets loyal users who have been purchasing from JD Health for six years, with a consistent monthly order for 72 months, showcasing diverse consumer profiles [3] - The ongoing orders reflect a narrative of care and lifestyle, driving JD Health to continuously optimize its products and services [3] Group 2: Market Trends and Consumer Behavior - During the New Year shopping festival, JD Health reported a 13-fold increase in daily visitor traffic for health gift products, with a 3.5-fold increase in searches for "New Year gift boxes" [3] - Searches for specific categories like fish oil, bird's nest, and protein powder doubled, indicating a shift towards more professional and precise gift choices among consumers [3] Group 3: Professional Services and Support - Along with the health products, users receive a year-long free one-on-one service from professional nutritionists, available for online consultations regarding nutritional products and dietary advice [5] - The nutritionist team will be available during the Spring Festival to provide tailored dietary suggestions for various demographics, including those with specific health concerns [5] Group 4: Strategic Direction - JD Health is integrating emotional connection with professional services, evolving health care from one-time gifts to long-term support, establishing itself as a reliable choice for health management during festive seasons [7]

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].

来源：央视网 2025年年底的北京，AI医疗问诊广告铺天盖地，从电视节目、手机软件到公交车站、商务楼电梯，随 处可见。 被魔性广告词"洗脑"的刘玉，今年30岁，却患有大大小小五六种慢性病，每个月都得跑两三次大型三甲 医院，一次就得耗费四五个小时的时间。抱着试一试的好奇心态，她下载了广告中的AI问诊软件，尝 试让"AI医生"为自己看病。 受访者供图 刘玉点开屏幕、打开软件，AI问诊的界面简洁明了、操作直观。她按照提示详细描述了皮肤症状，并 上传了红疹照片，询问是特应性湿疹还是过敏。不到一分钟，AI就反馈了"特应性湿疹"的初步判断，并 附上了用药建议和药品购买链接。 受访者供图 短短几分钟，刘玉就完成了以往需要数小时才能走完的问诊、开药、购药全流程。她既惊叹于这种高 效，又隐隐担忧AI是否真的靠谱。在她看来，或许能胜任日常健康咨询，但真生病时，她仍会选择去 医院，找真人医生确认AI的判断。 AI问诊在国内并非新鲜事物。2025年起，随着国产大模型技术实现显著突破，多家企业纷纷推出医疗 智能体产品，如医联的"未来医生"、京东健康的"AI医生大为"、蚂蚁集团的"阿福"、阿里的"夸克健 康"、百度健康的"文心健康管家" ...

2月7日，在云南省红河州建水县，一场特别的"新春游园会"让五十余名困境家庭的孩子们收获了新春的 第一份惊喜。在北京大学第六医院CAFF(Care For Family)花园公益项目红河州站营会中，由京东健康联 合举办的"新春游园会"环节受到了孩子们的热烈欢迎，孩子们通过努力参与活动赚取积分，兑换属于自 己的新春礼物。而这些礼物全部来自此前由CAFF花园项目联合京东健康、京东物流、京东科技共同发 起的"闲置变年货"公益行动中，社会各界爱心人士的捐赠。此次活动也得到了中国残疾人福利基金会的 支持，为当地困境家庭的孩子们送去了一份实实在在的新春温暖。 在这场游园会上，孩子们都能通过自己的努力"赢得"礼物。营会设置了多个活动环节，孩子们积极参 与、认真完成任务，积攒积分后兑换自己心仪的新春礼物。打开包装的那一刻，有的孩子抱着崭新的毛 绒玩偶笑得合不拢嘴，有的孩子小心翼翼地捧起一本从未读过的课外书。 CAFF花园项目所关注的领域也正得到国家层面的重视。2025年，中央财政支持的中国残疾人福利基金 会承办的"关爱精神健康困境家庭项目"在CAFF花园项目组的支持下全面启动，此次CAFF营会活动的联 合发起方、参与方也获得了 ...

Group 1 - The Hong Kong stock market saw a collective rise in AI application stocks, with notable increases such as Zhiyun up over 11% and Reading Group up 8% [1] - Other companies like Pony.ai, Fubo Group, and Xindong Company also experienced gains exceeding 6%, while Kingsoft Cloud and Dreamland Technology rose over 5% [1] - The report from Kaiyuan Securities highlighted ByteDance's launch of the Seedance 2.0 video generation model on the Jiemeng platform, which has sparked widespread evaluation and discussion in the AI industry due to its impressive performance [1] Group 2 - Zhiyun's stock price increased by 11.91% to 227.40, with a total market value of 101.39 billion and a year-to-date increase of 95.70% [2] - Reading Group's stock rose by 8.08% to 37.20, with a market capitalization of 37.99 billion and a year-to-date increase of 12.80% [2] - Other notable stock performances include Pony.ai up 6.46%, Fubo Group up 6.57%, and Xindong Company up 6.25%, with respective market values of 47.86 billion, 11.54 billion, and 41.69 billion [2]

Core Viewpoint - The Hong Kong stock market saw a collective rise in AI application stocks, indicating strong investor interest and confidence in the sector [1]. Group 1: Stock Performance - Zhihui Technology (智谱) surged over 11% [1] - Yuewen Group (阅文集团) increased by 8% [1] - Xiaoma Zhixing (小马智行), Fubo Group (阜博集团), Xindong Company (心动公司), and WeRide (文远知行) all rose over 6% [1] - Kingsoft Cloud (金山云), Chuangmeng Tiandi (创梦天地), and Minglue Technology (明略科技) experienced gains of over 5% [1] - MINIMAX-WP saw an increase of over 4% [1] - JD Health (京东健康), Chuangxin Qizhi (创新奇智), and Fanshi Intelligent (范式智能) rose over 3% [1] - Ping An Good Doctor (平安好医生) and Zhongyou Game (中手游) increased by nearly 3% [1]

Group 1 - The Hong Kong stock market saw a collective rise in AI application stocks, with notable increases such as Zhiyu up over 11% and Reading Group up 8% [1] - Other companies like Xiaoma Zhixing, Fubo Group, Xindong Company, and Wenyuan Zhixing experienced gains exceeding 6% [1] - The report from Kaiyuan Securities highlighted ByteDance's launch of the Seedance 2.0 video generation model on the Jiemeng platform, which has garnered significant attention and discussion within the AI industry due to its impressive performance [1] Group 2 - Zhiyu's stock rose by 11.91%, reaching a latest price of 227.400 with a total market value of 101.385 billion, marking a year-to-date increase of 95.70% [2] - Reading Group's stock increased by 8.08%, with a latest price of 37.200 and a market value of 37.999 billion, reflecting a year-to-date rise of 12.80% [2] - Xiaoma Zhixing's stock rose by 6.46%, priced at 110.400 with a market value of 47.863 billion, although it has seen a year-to-date decline of 5.88% [2]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].